Buy Biocon on every fall, says Deven Choksey

Deven Choksey of KR Choksey Investment Managers told CNBC-TV18, "For the last few years, Biocon has not been performing as much as its potential is. Now that the company has started performing and the potential is being exercised, to my mind that would be the comfort factor for the investors to come into this particular stock. Whole depends on the consistency under which they would produce the numbers.""Given the visibility that they have, there are all chances that they may have the consistency of this results performance coming in. I would be a buyer in this particular stock in every fall or a correction as I see it. In fact, many of the pharmaceutical companies I find are giving an opportunity to buy at a corrective level. So, certainly this could be one of them," he said.